Sat, Aug 23, 2014, 12:48 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • biobottom biobottom Sep 27, 2010 12:21 PM Flag

    sgen good for imgn

    I disagree. This article shows how SGEN was smarter than IMGN:

    "Last month, the FDA refused to even consider a breast cancer drug that combined Roche’s Herceptin with a chemotherapy using a linking technology developed by Immunogen, causing shares of Immunogen to plummet.
    Seattle Genetics says it expects to avoid Immunogen’s fate, because it has an agreement called a Special Protocol Assessment with the FDA. “The FDA has agreed that our pivotal trial design meets requirements for accelerated approval, including agreement that our pivotal trial population represents an unmet medical need,” a spokeswoman writes. She adds that the company believes the FDA’s decision on the Immunogen drug “relates to the evolving landscape and many therapies approved for the treatment of metastatic breast cancer, rather than any more broadly applicable principles.”

    -Long IMGN, wish I was long SGEN. -Biobottom

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • <"Last month, the FDA refused to even consider a breast cancer drug that combined Roche’s Herceptin with a chemotherapy using a linking technology developed by Immunogen, causing shares of Immunogen to plummet.>
      It wasnt the drug they refused to consider, it was the application, big difference.

    • really, how were they "smarter" Did IMGN design the trials, NO, that was Roche I believe. The only stupid thing IMGN did was buying into the idea FDA would approve a drug based on a single arm 100 pt trial because the patient population needs therapy. Well, it turns out FDA is run my corrupt morons, not a new finding. OREX and potentially SGEN investors will learn about the FDA problems in the near future. Good luck!

      • 1 Reply to bioimmunomabman
      • Bioimmuno: You answered part of the question as to why SGEN was smarter. Also, I was cringing at the paltry royalties IMGN accepted for itself on the drug.

        I don't think this time it was the FDA's incompetence so much that gave SGEN the advantage. It was more the unmet need SGEN was addressing with its drug.

        I still think the big difference in valuations justifies my big investment in IMGN over SGEN. But I am learning, too slowly, that the market always rewards the smarter companies, like Google, for instance.

 
IMGN
11.52+0.03(+0.26%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.